eneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn's disease-focused...
Subscribe now to see this Premium News article from
Alliance News Professional covers every UK stock in your portfolio. It goes beyond regulatory news and free web services to give your investment decisions an edge over the crowd.
Click for a FREE Trial
  • In The Know - Management and analyst comments that go beyond company announcements.
  • Flash headlines on all 2,400 London-listed companies before the news hits the open web.
  • Broker Ratings - The earliest tip-offs, many before the market opens.
  • Economic data and central bank flashes from UK, US and eurozone.
  • Taking AIM - Up to the minute market commentary on AIM stocks.
  • Over 500 news items per trading day for just £39.60 per month, and cancel at any time.
Try Alliance News FREE for 1 Month
Call us on +44 (0) 203 8794 460 to get started.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Set 2023 a Ott 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Ott 2022 a Ott 2023 Clicca qui per i Grafici di Astrazeneca